Polarx Limited

PXX

PolarX Ltd. is a mineral exploration and development company, which focuses on gold and copper exploration and its development. The company is headquartered in Subiaco, Western Australia and currently employs 1 full-time employees. The company went IPO on 2012-12-21. The firm is focused on copper, gold, and silver projects in United States of America. Its projects include Caribou Dome Copper project, Stellar Copper-Gold project, Humboldt Range Gold-Silver project, and Fourth of July project. The Caribou Dome Copper project comprises approximately 216 contiguous state mining claims and is located adjacent to the Company’s Stellar project. The claims cover a total area of 116 square kilometers (km2). The Stellar Copper-Gold project comprises approximately 231 contiguous State Mining Claims and is located immediately adjacent to the Company’s Caribou Dome Copper Project. The claims cover a total area of 150 Km2. The Humboldt Range Gold-Silver project comprises 364 lode mining claims in Nevada in two claim groups: Black Canyon and Fourth of July and is situated between two large-scale active mines: the Florida Canyon gold mine and the Rochester silver-gold mine.

Pexa Group Limited

PXA

PEXA Group Ltd. engages in the development and provision of electronic conveyancing system. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-07-01. The firm operates through three segments: PEXA Exchange, PEXA Digital Growth and PEXA International. PEXA Exchange segment comprises the Australian Electronic Lodgment Network (ELN) and financial settlement platform, which operates in the Australian electronic conveyancing market. The PEXA Exchange segment facilitates the collaboration between customers across the property ecosystem to enable the transfer and settlement of transactions in real property. PEXA Digital Growth segment seeks to provide data insights and digital services, transforming the experience of developing, buying and selling, settling, owning and servicing properties. PEXA International segment is an international version of the PEXA Exchange platform that is intended to provide digital property lodgment and settlement solutions for new jurisdictions. The PEXA Exchange operates in New South Wales, Victoria, Western Australia, and others.

Pharmaxis Ltd

PXS

Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm has a productive drug discovery engine, drug candidates in clinical trials and two respiratory products approved in global markets. Its lead drug candidate, PXS-5505, is an orally taken drug that inhibits the lysyl oxidase family of enzymes. Its PXS-5505 is used for the treatment of the blood cancer myelofibrosis, which affects one in 500,000 people. PXS-5505 is also being investigated as a potential treatment for other cancers, such as liver and pancreatic cancer. The company also has two respiratory products: Bronchitol and Aridol. Bronchitol is used for the treatment of cystic fibrosis. Its other drugs in development include PXS-5382 (LOXL2 inhibitor), PXS-6302 (topical pan LOX inhibitor), PXS-4728 (SSAO inhibitor), PXS-4699 (dual SSAO/MAOB inhibitor) and PXS-5370 (dual SSAO/MPO inhibitor).